
-
Evolus NasdaqGM:EOLS Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Location: 520 Newport Center Drive, Newport Beach, CA, 92660, United States | Website: https://www.evolus.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
664.5M
Cash
67.89M
Avg Qtr Burn
-5.754M
Short % of Float
17.04%
Insider Ownership
5.46%
Institutional Own.
85.36%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evolysse™ Details Nasolabial fold lines | Approved Quarterly sales | |
Jeuveau (prabotulinumtoxinA-xvfs) Details Glabellar lines , Benign tumor | Approved Quarterly sales | |
Jeuveau “Extra-Strength” Details Glabellar lines | Phase 2 Update |